Neuronox by Medytox: Korean Botulinum Toxin for Precise, Natural-Looking Results

Korea’s First Botulinum Toxin, Built on the Same Strain as Allergan Botox

Neuronox is a botulinum toxin type A product developed by Medytox Inc., a South Korean biopharmaceutical company with deep roots in the history of botulinum toxin science. First approved by the Korean Ministry of Food and Drug Safety in 2006, Neuronox was the first botulinum toxin brand developed and marketed in Korea, and has since been sold in more than 60 countries under various names including Meditoxin, Botulift, Cunox, and Siax.

Medytox was founded by scientists from the Korea Advanced Institute of Science and Technology (KAIST), who worked with the same Clostridium botulinum Hall A-hyper strain that was used to develop Allergan’s original Botox. As a result, Neuronox shares an identical bacterial strain origin with Allergan’s product, a distinction that sets it apart from other Korean toxins and has been confirmed through published genetic analysis.

What Neuronox Is

Neuronox is a freeze-dried lyophilized botulinum toxin type A formulation containing 100 units of clostridium botulinum toxin, human serum albumin, and sodium chloride per vial. It is reconstituted with saline before injection and administered in a 1:1 dose ratio with Botox, meaning clinical dosing protocols are directly transferable.

Neuronox works by temporarily blocking acetylcholine release at the neuromuscular junction, relaxing targeted muscles and smoothing dynamic wrinkles. Results typically become visible within 1 to 2 days of injection, which is faster onset than some competing formulations, and the effect generally lasts 3 to 6 months.

Low Tissue Permeability: A Key Clinical Advantage

One of the most clinically significant characteristics of Neuronox is its low tissue permeability, or diffusion rate. Compared to some other botulinum toxin formulations, Neuronox stays more precisely where it is injected, spreading less into surrounding tissue.

This makes Neuronox particularly well suited for delicate treatment areas where precision is critical, such as the periorbital region around the eyes and the perioral area around the lips. In these zones, unintended spread into adjacent muscles can cause drooping, asymmetry, or other unwanted effects. The limited diffusion profile of Neuronox reduces this risk, making it a preferred option for practitioners treating fine lines in high-precision areas.

Published clinical studies comparing Neuronox and Botox in the treatment of essential blepharospasm (eyelid spasm) have confirmed that the two products deliver comparable efficacy and safety outcomes, supporting their clinical interchangeability in appropriate settings.

Common Aesthetic Applications

Neuronox is used across a broad range of cosmetic indications, including glabellar lines, forehead lines, crow’s feet, perioral wrinkles, brow shaping, and treatment of hyperhidrosis. Its low diffusion profile makes it a particularly valued option for crow’s feet and fine lines around the mouth, where natural-looking, localized results are the goal.

Korean dermatologists have historically favored Neuronox (and its closely related counterpart Meditoxin) as one of the most widely used domestic botulinum toxin products, with surveys of Korean practitioners consistently placing it among the top-preferred brands in clinical practice.

Safety and Regulatory Status

Neuronox holds approval from the Korean MFDS and has received regulatory clearance in more than 20 countries. It has a well-established clinical record across both aesthetic and therapeutic indications, including treatment of spasticity and blepharospasm.

As with all botulinum toxin products, Neuronox should only be administered by a trained and licensed medical professional following thorough patient evaluation and anatomical assessment.